Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCSG 21: anastrozole + fulvestrant versus anastrozole in adjuvant early breast cancer with disseminated tumor cells
2005-005715-22Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Anastrozole + fulvestrant with Anastrozole alone (2 arms). Primary endpoint: Frequency of events after 12 months of randomized treatment. Started Jan 2006; status: terminated.
02
Drugs
anastrozolefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005715-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005715-22.